Sermonix Pharmaceuticals’ Lasofoxifene Demonstrates Anti-Estrogen Therapy Increases Immunotherapy Efficacy by Promoting Antitumor Activity of Eosinophils
01 oct. 2024 09h00 HE
|
Sermonix Pharmaceuticals Inc.
The findings were published Sept. 27 in the peer-reviewed journal Science AdvancesLasofoxifene was more effective than fulvestrant in inhibiting estrogen activity in mice models COLUMBUS, Ohio,...
Breast Cancer Index™ demonstrates its ability to predict preferential endocrine benefit irrespective of risk for HR+ early-stage breast cancer patients
17 déc. 2020 08h00 HE
|
Biotheranostics, Inc.
San Diego, CA, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine benefit irrespective of clinical risk for HR+ early-stage...
Biotheranostics to premiere new data on Breast Cancer Index™ and prediction of endocrine therapy benefit at SABCS 2020
08 déc. 2020 08h00 HE
|
Biotheranostics, Inc.
San Diego, CA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- New data on Biotheranostics’ Breast Cancer Index test will be highlighted at the 43rd annual San Antonio Breast Cancer Symposium (SABCS) being held...
Biotheranostics appoints Mark D. Pegram, MD as Chief Medical Advisor of Breast Oncology
03 déc. 2020 08h00 HE
|
Biotheranostics, Inc.
San Diego, CA, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Biotheranostics announces Mark D. Pegram, MD as Chief Medical Advisor of Breast Oncology in support of Breast Cancer Index, the only commercially...
Biotheranostics’ Breast Cancer Index® predicts benefit from two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the IDEAL trial
15 mai 2020 08h00 HE
|
Biotheranostics, Inc.
San Diego, CA, May 15, 2020 (GLOBE NEWSWIRE) -- Novel evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine response in distinct subgroups of HR+ early stage...
Biotheranostics’ Pivotal Clinical Study of the Breast Cancer Index® featured on the cover of the Annals of Oncology
24 févr. 2020 08h00 HE
|
Biotheranostics, Inc.
San Diego, CA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- A pivotal clinical study validating Breast Cancer Index earns the distinction of being selected for the cover of the Annals of Oncology. The...
Biotheranostics Launches Not Another Minute Campaign for its Breast Cancer Index® Test
11 déc. 2019 08h00 HE
|
Biotheranostics, Inc.
San Diego, CA, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Biotheranostics, Inc., announces the launch of its Not Another Minute campaign, revealing how Breast Cancer Index (BCI) is changing the game for...